The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma (Q39332317)

From Wikidata

Jump to navigation Jump to search

scientific article

Language	Label	Description	Also known as
English	The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma	scientific article

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

The impact of perioperative β blocker use on patient outcomes after primary cytoreductive surgery in high-grade epithelial ovarian carcinoma (English)

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Shitanshu Uppal

8

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

author name string

Ahmed Al-Niaimi

1

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Elizabeth L Dickson

2

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Cassandra Albertin

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Jennifer Karnowski

4

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Cassandra Niemi

5

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Ryan Spencer

6

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Mian M K Shahzad

7

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sandeep Saha

9

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Laurel Rice

10

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Amy Mc Nally

11

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

language of work or name

0 references

publication date

29 September 2016

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Gynecologic Oncology

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

143

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

3

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

521-525

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Survival impact of complete cytoreduction to no gross residual disease for advanced-stage ovarian cancer: a meta-analysis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.019

7 January 2021

Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cyclophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: the ICON3 randomised trial

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.019

7 January 2021

Surgical stress promotes tumor growth in ovarian carcinoma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.019

7 January 2021

Neuroendocrine influences on cancer biology

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.019

7 January 2021

Stress effects on FosB- and interleukin-8 (IL8)-driven ovarian cancer growth and metastasis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.019

7 January 2021

Meta-analysis of the effects of beta blocker on survival time in cancer patients

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.019

7 January 2021

Impact of beta blockers on epithelial ovarian cancer survival

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.019

7 January 2021

Clinical impact of selective and nonselective beta-blockers on survival in patients with ovarian cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.019

7 January 2021

Impact of beta blocker medication in patients with platinum sensitive recurrent ovarian cancer-a combined analysis of 2 prospective multicenter trials by the AGO Study Group, NCIC-CTG and EORTC-GCG.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.019

7 January 2021

The Hallmarks of Cancer

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.019

7 January 2021

Src activation by β-adrenoreceptors is a key switch for tumour metastasis.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.019

7 January 2021

Adrenergic modulation of focal adhesion kinase protects human ovarian cancer cells from anoikis

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.019

7 January 2021

β-Blocker usage and colorectal cancer mortality: a nested case-control study in the UK Clinical Practice Research Datalink cohort

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.019

7 January 2021

Beta-blocker usage and breast cancer survival: a nested case-control study within a UK clinical practice research datalink cohort.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.019

7 January 2021

Beta-blocker usage and prostate cancer survival: A nested case–control study in the UK Clinical Practice Research Datalink cohort

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.019

7 January 2021

Adrenergic blockers and the risk for common solid cancers: a case-control study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YGYNO.2016.09.019

7 January 2021

Identifiers

10.1016/J.YGYNO.2016.09.019

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

11 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q39332317&oldid=1820562360"